• 提示：详情请下载说明书。

• 产品描述： AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

• 靶点： CDK9/Cyclin T:10 nM (IC50);CDK5/p35:13 nM (IC50);cdk2/cyclin A:47 nM (IC50);Cdk4/cyclin D1:100 nM (IC50);cdk6/cyclin D3:170 nM (IC50);Cdk1/cyclin B:210 nM (IC50);CDK7/Cyclin H/MAT1:2400 nM (IC50);GSK3β:89 nM (IC50);Apoptosis; GSK-3; CDK

• 体内研究：
  AT7519 inhibits tumor growth in a human MM xenograft mouse model. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice

• 参考文献：
  1. Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36. 2. Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. 3. Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.

• 溶解性： DMSO  :  ≥  300  mg/mL  (716.49  mM)    H2O  :  8.33  mg/mL  (19.89  mM;  Need  ultrasonic)

• 保存条件： 2-8℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	2.388 ml	11.941 ml	23.883 ml
  5 mM	0.478 ml	2.388 ml	4.777 ml
  10 mM	0.239 ml	1.194 ml	2.388 ml
  50 mM	0.048 ml	0.239 ml	0.478 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *